Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended July 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medtronic (MDT) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.23 per share a year ago.
Medtronic appoints two new board directors following talks with activist investor Elliott Investment Management.
Medical-device maker Medtronic raised its fiscal 2026 profit forecast on Tuesday and said it expects a smaller-than-expected impact from the tariffs proposed by U.S. President Donald Trump.
The medical-device maker also plans to form committees focused on M&A and other growth areas.
Medtronic (NYSE:MDT) will report earnings on Tuesday, August 19, 2025. Over the last five years, the stock's next-day move following results has been highly unpredictable: it posted a positive one-day return in 50% of instances (median gain of 2.5%) and a negative one-day return in the other 50% (median loss of -3.8%).
In the closing of the recent trading day, Medtronic (MDT) stood at $91.98, denoting a -1% move from the preceding trading day.
Beyond analysts' top-and-bottom-line estimates for Medtronic (MDT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended July 2025.
Medtronic trades at a notable discount to peers as Q1 earnings loom, but rising costs and tariffs could test its resilience.
Medtronic (MDT) concluded the recent trading session at $91.24, signifying a +2.1% move from its prior day's close.
Medtronic (MDT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Medtronic (NYSE:MDT), which is renowned for inventing the world's first battery-operated implantable pacemaker, has over time earned respect as a worldwide leader in medical technology and has created substantial value for its shareholders. Although the company's advancements have influenced contemporary healthcare, its stock presents a more cautious narrative today.